Journal
OPHTHALMOLOGY
Volume 118, Issue 3, Pages 591-599Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2011.01.041
Keywords
-
Categories
Funding
- NEI NIH HHS [P30 EY014800-07, R01 EY017950, P30 EY014800, R01 EY017182] Funding Source: Medline
Ask authors/readers for more resources
Corneal neovascularization can lead to a devastating disease process that involves the breakdown of the limbal barrier and the formation of blood vessels in the cornea, leading to severe visual impairment. This review discusses the delicate balance between antiangiogenic and angiogenic factors that govern the antiangiogenic privilege of the cornea. Current treatment methods, clinical trials, and future prospects in the management of corneal neovascularization also are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available